ReviewElectrolyte & blood pressure : E & BP2014
Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies.
Review in Electrolyte & blood pressure : E & BP, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 230 citations in OpenAlex.
- Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: a Meta-analysis.Annals of surgical oncology · 2025Pooled it
- Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.The oncologist · 2024Pooled it
- The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury.Redox biology · 2024Trial
- The Protective Effects of Selenium Nanoparticles Against Metal Toxicity.Biological trace element research · 2026Review
- Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NADCells · 2026Article
- Assessing the hepatic and renal parameters of breast cancer patient blood samples before and after chemotherapy.Toxicology reports · 2026Article
- Targeting Cancer-Associated PCNA with AOH1996 Induces Mitotic Catastrophe and Enhances Cisplatin Therapy in Cervical Cancer.Cancer research communications · 2026Article
- PD1 cell membrane-coated Ru(ll)-Pt(lV) complex nanoparticles inhibit liver metastatic melanoma via cascade immune activation.Journal of nanobiotechnology · 2026Article
- Article
- Yiqi-Wenyang-Tiaoshen Decoction Reduces Cisplatin-Induced Acute Kidney Injury in Rats Through Autophagy and Apoptosis Signaling Pathways Based on Network Pharmacology and Experimental Validation.Mediators of inflammation · 2026Article
- TRPV1 blockade restores the baroreflex control of renal sympathetic nerve activity in cisplatin-induced renal injury in rats.Experimental physiology · 2025Article
- Targeted co-delivery of IL-10 and catalase for cooperative therapeutic effect on acute kidney injury.Bioactive materials · 2025Article
- Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity.Life (Basel, Switzerland) · 2025Article
- The extract of zedoary-turmeric protects rats' kidneys from damage caused by cisplatin.Journal of advanced veterinary and animal research · 2025Article
- Hybrid Platinum(IV)-Naproxen Nanostructured Drugs Reprogram Melanoma Cells and Overpower Cisplatin.Nanomaterials (Basel, Switzerland) · 2025Article
- Dual-function polyester nanoparticles for amplified anti-inflammatory effects.Science advances · 2025Article
- Three New Physalins fromMolecules (Basel, Switzerland) · 2025Article
- Protective Impacts ofLife (Basel, Switzerland) · 2025Article
- At-home 1-week hydration improves tolerance and treatment intensity of high-dose cisplatin in locally advanced head and neck cancer: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Optimization of lymphatic drug delivery system with carboplatin for metastatic lymph nodes.Scientific reports · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is one of the most widely used and highly effective drug for the treatment of various solid tumors; however, it has dose-dependent side effects on the kidney, cochlear, and nerves. Nephrotoxicity is the most well-known and clinically important toxicity. Numerous studies have demonstrated that several mechanisms, including oxidative stress, DNA damage, and inflammatory responses, are closely associated with cisplatin-induced nephrotoxicity. Even though the establishment of cisplatin-induced nephrotoxicity can be alleviated by diuretics and pre-hydration of patients, the prevalence of cisplatin nephrotoxicity is still high, occurring in approximately one-third of patients who have undergone cisplatin therapy. Therefore it is imperative to develop treatments that will ameliorate cisplatin-nephrotoxicity. In this review, we discuss the mechanisms of cisplatin-induced renal toxicity and the new strategies for protecting the kidneys from the toxic effects without lowering the tumoricidal activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.